secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001104659-25-061438
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools sells SomaLogic to Illumina for up to $425M; expects $550M cash at close
--------------------------------------------------------------------------------

- Upfront cash payment of $350M at closing plus up to $75M in near-term earnout milestones for total up to $425M.
- Retains 2% royalty on Illumina Protein Prep NGS kit sales for 10 years and co-exclusive Single SOMAmer rights.
- Transaction simplifies operating structure; expects to achieve adjusted EBITDA break-even post-close.
- Pro forma cash & equivalents of at least $550M at close to fund inorganic growth strategy.
- Expected close in H1 2026, subject to HSR clearance and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465925061438/0001104659-25-061438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465925061438/tm2518613d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer